A PYMNTS Company

EU: Commission picks a side on pay-for-delay controversy

By  |  June 3, 2013

In the first action taken since its initial look into the so-called pay-for-delay agreements of the pharmaceutical sector, the European Commission will reportedly fine a generic drug manufacturer in a move that suggests the regulator is ready to fight what it considers an anticompetitive, consumer-harming practice. Lundbeck, based in Denmark, as well as eight other generic drug makers will be fined by the Commission for entering into the agreements, which the Commission found to have blocked access to cheaper drugs for consumers. Since the probe was first launched into the sector in 2009, the Commission has determined that consumers could be hit with up to 20 percent markups for brand name prescription drugs. Both the US and the European Union are looking to clamp down on the anticompetitive practice. Reports say the EU will announce the fines later this month, according to Commission officials.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.